GUTS Stock Analysis: Buy, Sell, or Hold?
GUTS - Fractyl Health, Inc. Common Stock
$0.78
-0.05 (-6.29%)
▼
5d:
-0.13%
30d:
-14.8%
90d:
+80.07%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When GUTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GUTS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: GUTS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GUTS is currently trading at $0.78, which is considered slightly high relative to its 30-day fair value range of $0.74 to $0.90.
Technical Outlook: Technically, GUTS is in a downtrend. Immediate support is located at $0.65, while resistance sits at $0.92. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: GUTS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.24 (+533.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GUTS is in a downtrend. Immediate support is located at $0.65, while resistance sits at $0.92. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: GUTS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.24 (+533.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.74 -
$0.90
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 533.6% below Wall St target ($5.24)
Trading Range Analysis
30-Day Trading Range
$0.74 -
$0.90
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.65
Resistance Level
$0.92
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.20
Wall Street Target
$5.24
(+533.6%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: June 24, 2026 4:53 PM ET
Data refreshes hourly during market hours. Next update: 5:53 PM
Data refreshes hourly during market hours. Next update: 5:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GUTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
